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Introduction {#sec001}
============

According to the last WHO Tuberculosis (TB) report, in 2018 an estimated 10.0 million (range, 9.0--11.1 million) people fell ill with TB globally and an estimated 280,000 new and relapse TB cases occurred in the WHO European region. In addition, there were 77,000 estimated cases of multidrug-resistant (MDR) and rifampicin-resistant (RR) TB among notified pulmonary cases in the European region and the global average of isoniazid resistance without concurrent rifampicin resistance was 7.2% in new TB cases and 11.6% in previously treated TB cases \[[@pone.0232632.ref001]\].

The onset of this resistance is caused by incomplete treatment and/or inadequate therapy \[[@pone.0232632.ref002]\]. In fact, all patients initially receive standard daily anti-TB treatment based on preliminary results, which is then tailored accordingly as soon as drug susceptibility test results are available. \[[@pone.0232632.ref003]\]

*Mycobacterium tuberculosis* complex (MTBc) includes the species *M*. *tuberculosis*, *M*. *africanum*, *M*. *bovis*, *M*. *microti* and *M*. *canettii*, that cause tuberculosis disease, with almost identical nucleotide sequences and totally identical 16S rRNA sequences \[[@pone.0232632.ref004]\], The identification and drug susceptibility results *of* MTBc can require several weeks in smear-negative samples, and consequently optimal treatment may be delayed. In addition, according to the last ECDC Report \[[@pone.0232632.ref005]\], in European countries 17% of incident TB cases were extra-pulmonary (EPTB). EPTB is characterized by a very low bacterial load and remains undiagnosed for a long time in a considerable number of cases due to atypical presentation, often simulating neoplasia and/or inflammatory disorders \[[@pone.0232632.ref006]\].

A great deal of effort is currently focused on developing rapid and reliable molecular diagnosis of drug-resistant TB in order to initiate correct therapy \[[@pone.0232632.ref007]\].

MDR/MTB ELITe MGB^®^ Kit (ELITechGroup, Italy) is a new multiplex, ultra-sensitive, real time PCR assay (limit of detection 6 CFU/mL) used for the detection of MTBc DNA as well as Rifampicin and Isoniazid resistance \[[@pone.0232632.ref008]\]. The assay workflow of the ELITe InGenius^®^ system integrates the extraction and purification of nucleic acids, real-time PCR amplification, detection of the target sequence with melt-curve capability and result interpretation.

In this retrospective study, we assessed the performance of the MDR/MTB ELITe MGB^®^ Kit (ELITe) on pulmonary and extra-pulmonary specimens in comparison with culture as well as its ability to detect Rifampicin and Isoniazid resistance on different specimen matrices spiked with three drug-resistant strains. Agreement with Xpert MTB/RIF(Cepheid, USA) was also evaluated.

Materials and methods {#sec002}
=====================

Study design {#sec003}
------------

This is a retrospective study performed on frozen (-20°C) pulmonary and extra-pulmonary samples, collected between January 2017 and June 2018, and previously processed for MTBc detection by smear, culture and Xpert, at the Microbiology Unit of the S. Orsola-Malpighi Hospital, Bologna (Italy).

First, the sensitivity of the MDR/MTB ELITe MGB^®^ Kit (ELITe) was assessed on 50 sputum and 80 extra-pulmonary samples (20 urine, 20 biopsy, 20 cavitary fluid, 20 gastric aspirate) which were culture-positive for drug-susceptible MTBc. Specificity was evaluated on 50 MTBc culture-negative sputum samples and 80 MTBc culture-negative extra-pulmonary samples.

Secondly, detection of mutations in the *rpoB*, *katG* or *inhA* genes in different sample matrices was assessed. Previously processed MTBc culture-negative specimens were spiked with 3 MTBc isolates which were phenotypically resistant to Rifampicin and/or Isoniazid, carrying mutations in the *rpoB*, *katG* or *inhA* genes. In order to have a sufficient number of resistant samples for this diagnostic validation, 20 samples of each biological matrix were spiked with each of the 3 mutated MTBc strains, making a total of 300 spiked samples.

All frozen samples were anonymized and heat-inactivated for analysis with the MDR/MTB ELITe MGB^®^ Kit on ELITe InGenius^®^ system. The study was approved by the Ethics Committee of Area Vasta Emilia Centro (AVEC), Bologna, Italy (Study protocol n.137/2017/U/Tess). Informed consent was not required as the data were analysed anonymously.

Samples processing {#sec004}
------------------

Pre-treatment depended on the type of sample. Pulmonary and gastric aspirate samples were fluidified, if necessary, with Sputasol solution \[[@pone.0232632.ref009]\]. Urine and cavitary fluids (pleural, abdominal and ascitic fluids) were centrifuged and the supernatant removed to leave a final volume of 5 mL; urine pellets were also washed with 0.9% saline solution. Biopsies were mechanically homogenized with the addition of 0.9% saline solution to reach a volume of 5 mL. All specimens were digested and decontaminated using BBL MycoPrep^TM^ solution (Becton Dickinson, USA) according to the manufacturer's instructions, and re-suspended in 2.5 mL of phosphate buffered solution \[[@pone.0232632.ref010]\]. Two mL were used in the routine work-flow for MTBc detection by acid-fast microscopy (Ziehl-Neelsen stain), culture in solid media (Lowenstein-Jensen, Heipha Diagnostics, Germany),culture in liquid media (MGIT 960, Becton Dickinson), and Xpert MTB/RIF on GeneXpert platform (Xpert, Cepheid, USA). For this validation study 0.5 mL were stored at -20°C.

Phenotypic Antimicrobial Susceptibility Testing (AST) was performed by the ''gold standard" automatic MGIT 960 System (Becton Dickinson, USA) on all MTBc-positive cultures. GenoType MTBDRplus VER 2.0 (Hain Lifescience, Germany) was performed on MTBc strains phenotypically resistant to Rifampicin and/or Isoniazid to detect mutations in the *rpoB*, *katG* or *inhA* genes.

The complete microbiological characterization of the pulmonary and extra-pulmonary samples is shown in [Table 1](#pone.0232632.t001){ref-type="table"}.

10.1371/journal.pone.0232632.t001

###### Microbiological characteristics of samples included in the study.

![](pone.0232632.t001){#pone.0232632.t001g}

  Sample type            n\. of samples tested   AFB Microscopy positive   Xpert MTB/RIF positive   MTBc Culture positive
  ---------------------- ----------------------- ------------------------- ------------------------ -----------------------
  **Sputum**             160                     44                        50                       50
  **Urine**              100                     2                         8                        20\*
  **Biopsy**             100                     4                         20                       20
  **Cavitary Fluid**     100                     4                         18                       20
  **Gastric Aspirate**   100                     0                         18                       20

\*8 of the 20 MTBc positive urine samples were spiked at 20 CFU/ml with MTBc sensitive Strain 1.

AFB: Acid-fast bacilli.

Sample inactivation {#sec005}
-------------------

0.5 mL of each decontaminated sample were defrosted and inactivated at 95°C for 30 minutes in a dry block (ThermoStat plus, Eppendorf) where the temperature was checked manually with a thermometer. To verify MTBc inactivation, 250 μL of all specimens (n = 560) were cultured in solid media and incubated at 37°C for 8 weeks \[[@pone.0232632.ref001]\]. The remaining 250 μL were frozen (-20°C) for analysis with MDR/MTB ELITe MGB^®^ Kit on ELITe InGenius^®^ system.

MDR/MTB ELITe MGB^®^ Kit on ELITe InGenius^®^ system {#sec006}
----------------------------------------------------

200 μL of decontaminated and heat-inactivated sputum (n = 160) and extra-pulmonary samples (n = 400) were analysed by ELITe according to the manufacturer's instructions \[[@pone.0232632.ref008]\].

If the MTBc concentration is \>2,500 CFU/mL, corresponding to MTB (IS6110 probe) Ct ≤31, melting temperature (Tm) analysis is automatic. When Ct is \> 31, the sample is reported as "MTB DNA Detected, typing not feasible" and the Tm of the target probes (*rpoB1*, *rpoB2*, *rpoB3*, *rpoB4*, *katG*, *inhA*) can be checked by the operator. The sample is defined "RIF Resistance Negative" and "INH Resistance Negative" if all the Tm values fall within the limits reported in [Table 2](#pone.0232632.t002){ref-type="table"}.

10.1371/journal.pone.0232632.t002

###### Melting temperature (Tm) limits for rifampicin and isoniazid susceptibility.

![](pone.0232632.t002){#pone.0232632.t002g}

  Probe         Tm Limits          Outcome
  ------------- ------------------ -------------------------
  ***rpo*B1**   66.0 ≤ Tm ≤ 80.0   RIF Resistance Negative
  ***rpo*B2**   70.0 ≤ Tm ≤ 80.0   
  ***rpo*B3**   68.0 ≤ Tm ≤ 80.0   
  ***rpo*B4**   63.5 ≤ Tm ≤ 80.0   
  ***kat*G**    69.0 ≤ Tm ≤ 80.0   INH Resistance Negative
  ***inh*A**    66.0 ≤ Tm ≤ 80.0   

Samples with an invalid result, due to Internal Control failure (incorrect extraction or inhibitors carry-over), were re-tested starting from extracted DNA diluted 1:4 in water.

MTBc clinical strain characterization and titration {#sec007}
---------------------------------------------------

MTBc strains (n = 4) were characterized for mutation in *inhA*, *katG* or *rpoB* genes by GenoType MTBDRplus VER. 2.0. The results are shown in [Table 3](#pone.0232632.t003){ref-type="table"}.

10.1371/journal.pone.0232632.t003

###### Molecular characterization of MTBc strains by GenoType MTBDRplus.

![](pone.0232632.t003){#pone.0232632.t003g}

  Name                *rpo*B   *inh*A   *kat*G
  ------------------- -------- -------- --------
  **MTBc strain 1**   wt       wt       wt
  **MTBc strain 2**   mut3     wt       wt
  **MTBc strain 3**   wt       mut1     wt
  **MTBc strain 4**   wt       wt       mut1

To titre MTBc strains 1:10 serial dilutions of recent (no more than 2 days) positive MGIT of each MTBc isolate were prepared in 0.9% saline solution. 250 μL of each dilution were inoculated onto solid culture in order to obtain the number of CFU/mL.

Samples spiked with mutated MTBc strains {#sec008}
----------------------------------------

20 sputa, 20 urine samples, 20 biopsies, 20 cavitary fluids and 20 gastric aspirates, previously decontaminated and found Xpert and culture-negative, were spiked with 5,000 CFU/ml of MTBc mutated strain 2. This was repeated for strains 3 and 4 giving a total of 60 MTBc-resistant sputa and 240 MTBc-resistant extra-pulmonary samples.

Statistical analysis {#sec009}
--------------------

Determination of sensitivity, specificity, their 95% confidence intervals and Receiver Operating Characteristic (ROC) curve were performed using GraphPad Prism version 8.0.1 (Prism 8, San Diego, CA),.

To assess the agreement between phenotypic resistance and molecular typing obtained with ELITe as well as agreement between Elite and Xpert MTB/Rif, Cohen's κ statistics were calculated using Prism 8.

Results {#sec010}
=======

Sample inactivation {#sec011}
-------------------

Heat-inactivated specimens were MTBc culture-negative after 8 weeks of incubation at 37°C, demonstrating the efficacy of heat inactivation by dry block at 95°C.

Invalid results {#sec012}
---------------

Six (1.0%) of the 560 tests performed by ELITe were invalid: 2 (1.3%) of the 160 pulmonary samples and 4 (1.0%) of the 400 extra-pulmonary samples (2 biopsies, 1 cavitary liquid and 1 gastric aspirate). All samples with an invalid result were re-tested and a valid result obtained.

ELITe sensitivity and specificity {#sec013}
---------------------------------

The overall sensitivity and specificity on both pulmonary and extra-pulmonary samples compared to culture was 90.77% (95% CI: 0.8456--0.9464) and 99.23% (95% CI: 0.9577--0.9996) respectively. ROC curve ([Fig 1](#pone.0232632.g001){ref-type="fig"}) shows the tradeoff between sensitivity and specificity, and the parameters were calculated for each Ct value. The area under the ROC curve was 0.95 (95% CI: 0.92--0.98), with a p value \<0.0001.

![ROC curve of the ELITe system for the diagnosis of tuberculosis.\
TB diagnosis was assessed based on MTBc culture results.](pone.0232632.g001){#pone.0232632.g001}

Performance on pulmonary samples {#sec014}
--------------------------------

As shown in [Table 4](#pone.0232632.t004){ref-type="table"}, 49 of the 50 MTBc culture-negative sputum samples tested by ELITe were found negative and 1 positive. 49 of the 50 MTBc culture-positive samples tested by ELITe were found positive and 1 negative. Therefore, the overall sensitivity and specificity of ELITe compared to culture were 98.0% \[CI: 89.35--99.95\] and 98.0% \[CI: 89.35--99.95\] respectively. Six of the 50 MTBc culture-positive sputa were smear-negative; 5 of these were ELITe positive.

10.1371/journal.pone.0232632.t004

###### Agreement between MDR/MTB Elite MGB^®^ and MTBc culture.

![](pone.0232632.t004){#pone.0232632.t004g}

  MDR/MTB ELITe MGB^®^                     SPUTUM (agreement %)   URINE (agreement %)   BIOPSY (agreement %)   CAVITARY FLUID (agreement %)   GASTRIC ASPIRATE (agreement %)
  ---------------------------------------- ---------------------- --------------------- ---------------------- ------------------------------ --------------------------------
  **MTBc culture negative**                49/50 (98)             20/20 (100)           20/20 (100)            20/20 (100)                    20/20 (100)
  **MTBc culture positive**                49/50 (98)             16/20 (80)            17/20 (85)             19/20 (95)                     17/20 (85)
  **Spiked with MTBc strain 2 (*rpoB*)**   20/20 (100)            20/20 (100)           20/20 (100)            20/20 (100)                    20/20 (100)
  **Spiked with MTBc strain 3 (*inhA*)**   20/20 (100)            20/20 (100)           20/20 (100)            20/20 (100)                    20/20 (100)
  **Spiked with MTBc strain 4 (katG)**     20/20 (100)            20/20 (100)           20/20 (100)            20/20 (100)                    20/20 (100)

Molecular typing was feasible in 47 of the 49 drug susceptible MTBc-positive sputum samples with 100% agreement between genotypic susceptibility to Isoniazid and Rifampicin and phenotypic results. For these samples the mean ELITe MTBc Ct value was 24.2 ±4.0 (range: 18.13--34.11) and Time to Positivity in liquid culture (TTP) was 7.1 ± 3.0 days.

Molecular typing was not feasible in 2 of the 49 drug susceptible MTBc-positive samples: MTB Ct Values were 35.90 and 37.79 respectively, smear microscopy was negative and mean TTP was 14.5±3.5 days.

Sputum samples (n = 60) spiked with 3 mutated MTBc strains were found positive with 100% molecular agreement for the *inhA*, *katG* and *rpoB* genes ([Table 4](#pone.0232632.t004){ref-type="table"}).

[Table 5](#pone.0232632.t005){ref-type="table"} shows molecular agreement between ELITe and Xpert for the 100 sputa tested with Xpert. 49 were Xpert-, ELITe- and culture-positive, 49 were Xpert-, ELITe- and culture-negative. Two samples gave discordant results (1 was Xpert and MTBc culture-positive/ELITe negative and 1 was Xpert and MTBc culture-negative /ELITe positive), with an overall agreement of 98% \[K: 0.96, CI: 0.905--1\].

10.1371/journal.pone.0232632.t005

###### Molecular agreement between MDR/MTB ELITe MGB^®^ Kit and Xpert MTB/Rif.

![](pone.0232632.t005){#pone.0232632.t005g}

  Sample types           n\. of samples tested with Xpert   Agreement (%)   95% C.I.    Cohen's kappa
  ---------------------- ---------------------------------- --------------- ----------- ---------------
  **Sputum**             100                                98              90.5--100   0.960
  **Urine**              30                                 90              45.2--100   0.734
  **Biopsy**             40                                 92.5            68.9--100   0.850
  **Cavitary Fluid**     40                                 97.5            85.3--100   0.950
  **Gastric Aspirate**   40                                 92.5            68.2--100   0.848

Performance on extra-pulmonary samples {#sec015}
--------------------------------------

As shown in [Table 4](#pone.0232632.t004){ref-type="table"}, all (n = 80) MTBc culture-negative extra-pulmonary samples (urine, biopsy, cavitary fluid and gastric aspirate) were found negative by ELITe, with a specificity of 100% \[CI: 95.49--100\].

Excluding 8 spiked urine samples, in MTBc culture-positive samples (n = 72), the overall sensitivity of ELITe on extra-pulmonary samples was 86.3% \[CI: 76.73--92.93\]; sensitivity was 80% \[CI: 56.34--94.27\] for urine, 85% \[CI: 62.11--96.79\] for biopsy, 95% \[CI: 75.13--99.87\] for cavitary fluid and 85% \[CI: 62.11--96.79\] for gastric aspirate. In 62 smear-negative extra-pulmonary samples, the overall sensitivity of ELITe was 82.3% \[CI: 70.47--90.80\].

Molecular typing was feasible in the following samples: 3/12 urine primary samples (mean MTBc Ct Value: 31.1±4.1), 12/17 biopsy (mean MTBc Ct Value: 30.0±3.9), 13/19 cavitary fluid (mean MTBc Ct Value: 30.1±2.6) and 2/17 gastric aspirate (mean MTBc Ct Value: 30.6±3.1), with 100% agreement with the phenotypic test. In culture-positive samples where molecular typing was not feasible (n = 35), the mean MTB Ct Value was 38.0 ±2.0; these samples were smear-negative. TTPs were 14.3 ±3.2 days in samples where molecular typing was not feasible and 12.2 ±4.0 days in samples with feasible molecular typing. Extra-pulmonary samples (60 per matrix) spiked with 3 mutated MTBc strains were found positive with 100% molecular agreement for the *inhA*, *katG* and *rpoB* genes ([Table 4](#pone.0232632.t004){ref-type="table"}).

The overall molecular agreement between ELITe and Xpert for extra-pulmonary samples was 93.33% \[CI: 0.781--0.945, k = 0.863\]; the agreement for each biological matrix is shown in [Table 5](#pone.0232632.t005){ref-type="table"}. The best result was obtained with cavitary fluid (97.5%). Discordant results were due to 7 MTBc culture-positive samples being found Xpert positive/ELITe negative, and 3 MTBc culture-positive samples being found Xpert negative/ELITe positive.

Discussion {#sec016}
==========

This is the first assessment of MDR/MTB ELITe MGB^®^ Kit (ELITe) performance on pulmonary and extra-pulmonary samples in comparison to MTBc culture in the literature to date.

The overall (pulmonary and extra-pulmonary) sensitivity and specificity compared to MTBc culture were 90.77% and 99.23% respectively, and ROC analysis (AUC = 0.95) showed the high accuracy of the ELITe system for the diagnosis of tuberculosis.

On sputum samples, both the sensitivity and specificity of ELITe were excellent (98% and 98% respectively); only two samples gave discordant results. One sputum was ELITe negative and culture-positive; in this case MTBc concentration was very low as shown by a long time to positivity (TTP) in liquid media (15.6 days). On the other hand, one sputum sample was ELITe positive but MTBc culture-negative. For this sample we can speculate a false positive result by ELITe or a true MTBc positive paucibacillary sample where culture isolation was not achieved; the high Ct value (Ct = 36) measured by ELITe could support the latter hypothesis, but unfortunately clinical data were not available.

One limit of this study is that most sputum samples were smear-positive, therefore sensitivity on smear-negative samples could not be evaluated. However, 5 of the 6 smear-negative samples were ELITe positive. In our setting most sputa from TB patients are smear-positive, while most smear-negative pulmonary samples are bronchoalveolar fluids, which were not included in this study.

For extra-pulmonary samples including urine, cavitary fluids, biopsy and gastric aspirates, ELITe specificity was 100% and sensitivity was 86.3%. Furthermore, sensitivity in smear-negative MTBc culture-positive extra-pulmonary samples was 82.3%. Most studies addressing the detection of MTBc by molecular tests on extra-pulmonary samples have been based on Xpert MTB/RIF (according to Tortoli *et al*. sensitivity: 81.3% \[[@pone.0232632.ref006]\]; Mazzola *et al*. sensitivity: 83.6% \[[@pone.0232632.ref011]\]; Lombardi *et al*. sensitivity: 76.8% \[[@pone.0232632.ref012]\]) or on Xpert Ultra systems (according to Perez-Risco *et al*. sensitivity in smear-negative e-PTB: 75.9% \[[@pone.0232632.ref013]\]; Opota *et al*. sensitivity: 83.7% \[[@pone.0232632.ref014]\]). Data obtained with ELITe are in line with results obtained with those systems.

Molecular typing to detect Isoniazid and Rifampicin resistance was feasible in 96% sputum and 46% extra-pulmonary culture-positive samples. In sputa where typing was not feasible, MTBc Ct values and TTP in liquid culture were higher than those in which typing was feasible (Ct values 36.8 vs. 24.2, TTP 14.5 vs. 7.1 days, respectively), indicating a low concentration of MTBc DNA. Similar results were obtained for extra-pulmonary samples.

Detection of Rifampicin and Isoniazid resistance by ELITe was assessed on 60 MTB spiked sputum samples and 240 MTB spiked extra-pulmonary samples, with a molecular agreement of 100% for the *inhA*, *katG* and *rpoB* genes. One limit of this study is that only 3 mutated MTBc strains were used, which do not cover the spectrum of possible mutations that confer resistance to Isoniazid and Rifampicin. However, the entire spectrum of mutations was previously evaluated by the Company as described in the MDR/MTB ELITe MGB^®^ Kit Instruction for Use \[[@pone.0232632.ref008]\].

Finally, the molecular agreement between ELITe and Xpert was excellent for sputum, cavitary fluid, biopsy and gastric aspirate, and good for urine, as shown by Cohen's Kappa. However, the sample volume used by the two assays is different (200 μL for ELITe, 500 μL for Xpert) and this difference could impact the assay comparison. In contrast to Xpert, ELITe identifies Isoniazid resistant strains, which would otherwise not be detected before phenotypic DST results or by a combination of Xpert and Line Probe Assay, such as GenoType MTBDRplus.

In this study, the overall rate of invalid results was very low (1.0%), with no difference between pulmonary and extra-pulmonary samples, confirming the robustness of the amplification process. Invalid results were lower than those obtained with Xpert (2.8%) described by Lombardi at al. \[[@pone.0232632.ref012]\].

This study was performed on frozen samples stored at -20°C over a period of 18 months prior to assay. However, we can speculate that storage did not reduce specimen stability, as shown in our previous study with Xpert Ultra, where we demonstrated that the detection rate of the assay did not significantly decrease despite long-term storage of pulmonary and extra-pulmonary samples \[[@pone.0232632.ref015]\]. In order to perform the test in a Biosafety Level 2 laboratory, samples were previously inactivated. MTBc inactivation was achieved using a dry-block at 95°C for 30 minutes, this allowed easier and safer heat-inactivation compared to a boiling water bath, as previously shown by other Authors \[[@pone.0232632.ref016], [@pone.0232632.ref017]\].

In conclusion, the high sensitivity and specificity results obtained in this study on a large sample size of specimens provide evidence for the use of MDR/MTB ELITe MGB^®^ Kit in combination with ELITe InGenius^®^ for the diagnosis of MTB complex as well as Rifampicin and Isoniazid resistance in both pulmonary and extra-pulmonary samples. This automated system simplifies the laboratory workflow, has a fast turnaround time (less than 3 hours) and is an aid in choosing appropriate therapeutic treatment and patient management.

The authors thank ELITechGroup for providing MDR/MTB ELITe MGB^®^ Kit reagents, Dr. Paola Monari and Dr. Eleonora Gatti for technical support and Jackie Leeder, BSc, for English language editing.

10.1371/journal.pone.0232632.r001

Decision Letter 0

EHTESHAM

HASNAIN SEYED

Academic Editor

© 2020 HASNAIN SEYED EHTESHAM

2020

HASNAIN SEYED EHTESHAM

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

31 Mar 2020

PONE-D-20-03632

Simultaneous detection of Mycobacterium tuberculosis complex and resistance to Rifampicin and Isoniazid by MDR/MTB ELITe MGB® Kit for the diagnosis of tuberculosis

PLOS ONE

Dear Dr. Lombardi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 15 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

HASNAIN SEYED EHTESHAM

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Some classic publications on drug resistance published several years ago are missing in the references, the authors may need to include them. I recommend a minor revision.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for including the following ethics statement for participant consent on the submission details page:

\'Consent was not required as the data were analyzed anonymously.\'

Please also include this consent information in the ethics statement in the Methods section of your manuscript.

3\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Comments to the authors:

The retrospective study titled "Simultaneous detection of Mycobacterium tuberculosis complex and resistance to Rifampicin and Isoniazid by MDR/MTB ELITe MGB® Kit for the diagnosis of tuberculosis" by Bisognin F et al. demonstrated the use PCR based MDR/MTB ELITe MGB® Kit in the detection of Mycobacterium tuberculosis complex (MTBc). Timely detection is required for efficient management of TB cases word-wide. The diagnosis methods which can be operated in resource limited settings are required for efficient management of tuberculosis or disease caused by the MTBc. In this retrospective study the authors used the stored samples isolated from pulmonary, and extra-pulmonary sites. They compared their results with AFB staining, culture as well as Xpert MTB/RIF. Although, they showed good agreement in specificity and sensitivity with all the known methods used for the detection of MTBc in pulmonary and extra-pulmonary samples. To demonstrate their results in statistically significant and more reliable way the authors should generate ROC curve for their findings and include in the manuscript. This will accurately demonstrate their findings in statistically significant and meaning full way. The manuscript is well written and organized. The conclusions drawn are well supported by their data. The authors should have included more number of cases of smear negative samples. The authors mentioned MTBc through the manuscript. They should introduce few sentences describing species included. The manuscript could be accepted for publication after careful revision and addition of ROC analysis.

Reviewer \#2: Current manuscript is technically sound and evaluated in a planned way. Statistical analysis is done appropriately.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Mohd Shariq

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Manuscript Re-submission to PLOS ONE: Response to Reviewers (PONE-D-20-03632)

Title: Simultaneous detection of Mycobacterium tuberculosis complex and resistance to Rifampicin and Isoniazid by MDR/MTB ELITe MGB® Kit for the diagnosis of tuberculosis

Authors: Francesco Bisognin, Giulia Lombardi, Chiara Finelli, Maria Carla Re, Paola Dal Monte

Dear Editor,

we would like to submit the revised version of our manuscript (PONE-D-20-03632) in order to make it suitable for publication in PLOS ONE.

We would like to thank you and the Reviewers for the useful comments provided. Based on all comments received, we have revised the original manuscript and added the ROC curve required.

The point-by-point responses to journal requirements and reviewers' comments as well as the changes made to the original manuscript are described below.

Additional Editor Comments (if provided):

Some classic publications on drug resistance published several years ago are missing in the references, the authors may need to include them. I recommend a minor revision.

Thank you for your comment: we added 2 references about drug resistant MTBc in the Introduction section:

• Rockwood N, Abdullahi LH, Wilkinson RJ, Meintjes G. Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis. PLoS ONE. 2015; 10(9):e 0139017.

• Albanna AS, Menzies D. Drug-resistant tuberculosis: what are the treatment options?. Drugs. 2011; 71(7):815-25.

JOURNAL REQUIREMENTS:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Plos One style requirements have been satisfied.

2\. Thank you for including the following ethics statement for participant consent on the submission details page:

\'Consent was not required as the data were analyzed anonymously.\'

Please also include this consent information in the ethics statement in the Methods section of your manuscript.

We included the sentence required about the Informed Consent in the Material and Method section (lines 94-95).

3\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Here, we provide the DOI necessary to access our data.

Please update our Data Availability statement to: "All de-identified data used in this study are available from the Database Bisognin F et al ELITe, held in the Figshare public repository at the following URL: <https://doi.org/10.6084/m9.figshare.12123585.v1>.

Reviewers\' comments:

Reviewer \#1: Comments to the authors:

The retrospective study titled "Simultaneous detection of Mycobacterium tuberculosis complex and resistance to Rifampicin and Isoniazid by MDR/MTB ELITe MGB® Kit for the diagnosis of tuberculosis" by Bisognin F et al. demonstrated the use PCR based MDR/MTB ELITe MGB® Kit in the detection of Mycobacterium tuberculosis complex (MTBc). Timely detection is required for efficient management of TB cases word-wide. The diagnosis methods which can be operated in resource limited settings are required for efficient management of tuberculosis or disease caused by the MTBc. In this retrospective study the authors used the stored samples isolated from pulmonary, and extra-pulmonary sites. They compared their results with AFB staining, culture as well as Xpert MTB/RIF. Although, they showed good agreement in specificity and sensitivity with all the known methods used for the detection of MTBc in pulmonary and extra-pulmonary samples. To demonstrate their results in statistically significant and more reliable way the authors should generate ROC curve for their findings and include in the manuscript. This will accurately demonstrate their findings in statistically significant and meaning full way. The manuscript is well written and organized. The conclusions drawn are well supported by their data. The authors should have included more number of cases of smear negative samples. The authors mentioned MTBc through the manuscript. They should introduce few sentences describing species included. The manuscript could be accepted for publication after careful revision and addition of ROC analysis.

Many thanks for your comments.

As you suggested, we generated a ROC curve (Figure 1) to improve our statistical analysis. ROC analysis (AUC= 0.95) showed the high accuracy of the ELITe system for the diagnosis of tuberculosis.

Therefore we added the description of the statistical analysis used (in the Material and Method section), a paragraph in the Results section (lines 182-192), and a sentence in the Discussion section (lines 250-252).

Furthermore, as you suggested, we added a sentence describing MTB complex in the Introduction section (lines 49-51).

Reviewer \#2: Current manuscript is technically sound and evaluated in a planned way. Statistical analysis is done appropriately.

Many thanks for your positive comments.

We hope that the revised manuscript can now be accepted for publication in PLOS ONE.

Thank you very much for your kind consideration.

Yours faithfully,

Giulia Lombardi

Corresponding author:

Dr. Giulia Lombardi, PhD

Department of Experimental, Diagnostic and Specialty Medicine - Microbiology Unit

University of Bologna - S. Orsola Malpighi University Hospital

Via Massarenti 9 - 40138 Bologna - Italy
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Dear Dr. Lombardi,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

HASNAIN SEYED EHTESHAM

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors have revised the manuscript. The only major issue related to statistical analyses and these have been addressed.
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Dear Dr. Lombardi:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof HASNAIN SEYED EHTESHAM

Academic Editor

PLOS ONE
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